Compare ARK Genomic Revolution ETF (ARKG) vs Cigna Corp (CI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Cigna Corp — how do they compare? ARK Genomic Revolution ETF trades at $40.69, while Cigna Corp trades at $301.5 (market cap $77.63B). The key difference: Cigna Corp pays a 2.13% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | CI | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.57 | $311.00 |
52-Week Low | $23.09 | $244.41 |
Market Cap | — | $77.63B |
Enterprise Value | — | $100.73B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Cigna (CI) trades at $293.46, up 0.57% on the day, with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.44 and P/S of 0.28. Recent news highlights strategic initiatives, including AI integration in pharmacy services. The current price is near the consensus price target of $339.82, indicating potential upside.
The outlook for CI is positive, driven by earnings momentum, a favorable analyst consensus, and strategic growth investments. Key risks include regulatory challenges, as seen in a recent lawsuit in Tennessee, and competitive pressures in the healthcare sector. Net cash flow turned negative in 2025, which warrants monitoring. The stock presents a value opportunity with a solid dividend, but investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →
